Register to use all the features of this website, including selecting clinical areas of interest and “favourite” articles, taking part in quizzes and much more.
Hint: If you are a General Practitioner your username may be your MCNZ#
About us | FAQ | Contact us | Terms of use
Interactive quizzes are based on material found in Best Practice Journal and Best Tests. Initially, quizzes are posted out with journals and GPs are invited to submit their answers for CME credits.
Register or Log in to take part in quizzes.
Login to my bpac.
Don't have an account? Register to use all the features of this website, including selecting clinical areas of interest, taking part in quizzes and much more.
BPJ 78 April 2017
The funded brand of amiodarone has now changed, see: Antiarrhythmic medicine brand changes: flecainide and amiodarone
Two brands of amiodarone are currently subsidised in New Zealand; Aratac (a generic brand) and Cordarone-X (the innovator brand).
Transdermal oestradiol patches are now fully subsidised, without the need for Special Authority approval, for the treatment of menopausal symptoms.
For more recent recommendations, please see: "Menopausal hormone therapy: where are we now?"